Uniphos Enterprises Ltd

Financial results and approvals

• Board approved unaudited quarter ended 30 June 2026 results.
• Total income reported Rs 16.46 lakh; net loss Rs 118.97 lakh for the quarter.
• EPS (basic/diluted) for quarter ended 30 June 2026: (0.17).
• Audit Committee reviewed; Limited Review by B S R & Co. LLP; unmodified conclusion.

Dividend and shareholder action

• Dividend of Rs 3.50 per equity share recommended by Board; AGM approved on 7 Aug 2026.

Regulatory and audit

• Limited review report dated 12 Aug 2026; statutory auditors’ unmodified conclusion.
• Report filed with stock exchanges and available on company website.

Corporate structure disclosure

• Company has no subsidiary, joint venture, or subsidiary; consolidated financial statements not applicable.

AGM Details

• Date and time: 7 August 2026, 10:30 IST.
• Mode: conducted via VC/OAVM.
• Voting cut-off date for eligibility: 31 July 2026.

Key Resolutions

• Ordinary: Receive, consider and adopt audited financial statements.
• Ordinary: Declare a dividend on equity shares.
• Special: Appoint Arun Chandrasen Ashar as Chairman and Non-Executive Director, retiring by rotation.

Voting Results

• Resolution 1 passed by majority; small opposition.
• Resolution 2 passed by majority; minimal opposition.
• Resolution 3 passed by majority; minimal opposition.

Dividend

• Dividend declared on equity shares for the financial year.

Director Changes

• Arun Chandrasen Ashar reappointed as Chairman and Non-Executive Director.

Auditors

• No auditor changes disclosed.

Related Party Transactions

• No material related party transactions approved.

Other Material Approvals

• No ESOPs or other material approvals disclosed.

Overview

• Standalone BRSR for FY 2025-26 submitted; main activities are trading agro commodities and investments.
• No manufacturing plants or direct workers; employees are on deputation.
• Reporting boundary is standalone; disclosures limited due to the company's non-manufacturing scope.

Key ESG Risks & Opportunities

• ESG/regulatory compliance risk due to potential non-compliance; mitigated by board oversight; negative financial implications.
• Concentration risk: 100% purchases from a single trading house; one supplier; governance review.
• High related-party exposure: 98.41% of investments in related parties; Nerka Chemicals holds 73.29%.
• Anti-corruption policy not standalone; ethics framework exists via Code of Conduct and Whistleblower Policy.
• Board BR training conducted; 100% coverage for directors.

Governance & Policy Highlights

• BR governance is overseen by Board and management; some BR policies approved by the Board.
• Highest BR oversight authority: Managing Director.
• No dedicated sustainability committee; BR policies translated into procedures.
• Policies cover NGRBC principles; procedures applied; value-chain policy not extended.
• Complaint handling: Whistleblower and Code of Conduct policy; board reviews BR.
• No external BR review by independent agency; internal evaluation.
• Policies translated; some approvals by Board per statutory requirements.

Social Responsibility & Workforce

• Total workforce comprises deputed employees; no permanent staff or workers.
• Board gender diversity: 2 of 6 women; KMP female: 1 of 3.
• Health and wellbeing benefits provided by deputation companies; health and accident insurance coverage.
• BR training: 100% coverage for board and KMPs.
• Whistleblower policy and investor grievance mechanism; quarterly Board reporting.
• Accessibility for differently abled; equal opportunity policy in Code of Conduct.

Environmental Performance

• Energy use limited to asset maintenance; no manufacturing, energy data not disclosed.
• PAT scheme not applicable; not designated consumer.
• Water usage limited to day-to-day management; volumes not disclosed.
• No Scope 1 or 2 emissions due to absence of manufacturing.
• No environmental certifications or targets disclosed.
• Waste data not applicable due to limited operations.
• No GHG reduction projects.

Stakeholder Engagement & Complaints

• Key stakeholder groups include investors, employees, regulators, and communities.
• Engagement channels include website, stock exchanges, whistleblower policy, and email.
• Shareholder complaints: five filed in FY26, all resolved.
• Investor grievances reported to Board quarterly.
• Whistleblower policy enables community and employee grievances reporting.
• Data privacy framework not formal; no data breaches reported.

Other Notable Metrics

• Investments in related parties account for 98.41% of total investments; Nerka Chemicals holds 73.29%.
• Turnover split: 55.92% trading; 44.08% income from investments.
• Export share of turnover: 0%.
• Key Managerial Personnel remuneration: ₹144.54 Lakhs.
• Board female representation: 33.33%; KMP female: 33.33%.
• CSR not applicable under Companies Act; not disclosed.
• No external BR assurance; not applicable.
• Data privacy policy framework not present; no data breaches reported.

Dematerialisation/rematerialisation status

• Dematerialisation requests for the reporting quarter were processed and confirmed to the depositories.
• Securities dematerialised during the period have been listed on the exchanges where previously issued securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled after verification, with the depository substituted as registered owner.
• The depository name has been substituted in the register of members within prescribed timelines.

AGM Details

• AGM on Aug 7, 2026 at 10:30 IST; via VC/OAVM.

Dividend Proposal

• Dividend proposed: 175% = ₹3.50 per equity share.
• Record date for entitlement: July 17, 2026.

Notice and Materials

• Annual Report and AGM Notice will be sent electronically.

Voting Status

• Voting results not available yet; AGM to be conducted on Aug 7, 2026.

Uniphos Enterprises Ltd — Trading window closed from July 1, 2026 until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.